Catalio Capital Management LP Makes New Investment in Fulcrum Therapeutics, Inc. $FULC

Catalio Capital Management LP bought a new position in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 201,301 shares of the company’s stock, valued at approximately $2,277,000. Catalio Capital Management LP owned 0.37% of Fulcrum Therapeutics at the end of the most recent quarter.

Several other large investors have also modified their holdings of FULC. Aberdeen Group plc grew its stake in Fulcrum Therapeutics by 135.0% in the 3rd quarter. Aberdeen Group plc now owns 137,961 shares of the company’s stock worth $1,269,000 after acquiring an additional 79,265 shares during the period. Braidwell LP acquired a new position in shares of Fulcrum Therapeutics in the 3rd quarter valued at $2,019,000. Boothbay Fund Management LLC boosted its holdings in shares of Fulcrum Therapeutics by 104.2% in the 3rd quarter. Boothbay Fund Management LLC now owns 678,414 shares of the company’s stock valued at $6,241,000 after purchasing an additional 346,136 shares during the last quarter. Suvretta Capital Management LLC lifted its holdings in shares of Fulcrum Therapeutics by 5.9% during the 3rd quarter. Suvretta Capital Management LLC now owns 5,381,000 shares of the company’s stock valued at $49,505,000 after acquiring an additional 298,100 shares in the last quarter. Finally, GSA Capital Partners LLP lifted its holdings in shares of Fulcrum Therapeutics by 256.4% during the 3rd quarter. GSA Capital Partners LLP now owns 116,068 shares of the company’s stock valued at $1,068,000 after acquiring an additional 83,505 shares in the last quarter. 89.83% of the stock is currently owned by institutional investors and hedge funds.

Fulcrum Therapeutics Price Performance

FULC stock opened at $3.50 on Thursday. Fulcrum Therapeutics, Inc. has a 12 month low of $2.83 and a 12 month high of $15.74. The firm has a market cap of $233.21 million, a PE ratio of -3.04 and a beta of 2.93. The firm has a 50 day simple moving average of $6.32 and a 200 day simple moving average of $8.63.

Fulcrum Therapeutics (NASDAQ:FULC) last released its quarterly earnings results on Monday, April 27th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.06. As a group, sell-side analysts expect that Fulcrum Therapeutics, Inc. will post -0.76 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. JPMorgan Chase & Co. lowered shares of Fulcrum Therapeutics from an “overweight” rating to an “underweight” rating in a report on Wednesday, June 3rd. Cantor Fitzgerald downgraded shares of Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, June 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research report on Tuesday, April 21st. Stifel Nicolaus downgraded shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and set a $3.00 price objective for the company. in a research report on Tuesday, June 2nd. Finally, Leerink Partners lowered shares of Fulcrum Therapeutics from an “outperform” rating to a “market perform” rating and set a $4.00 target price for the company. in a research note on Tuesday, June 2nd. One research analyst has rated the stock with a Buy rating, seven have issued a Hold rating and four have issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Reduce” and a consensus price target of $8.20.

Fulcrum Therapeutics Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small?molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.